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It has been pointed out that immunosuppression with cytotoxic, nonsteroidal drugs
is associated with the development of cytomeglovirus (CMV) infection after renal
transplantation, and that without such immunosuppression infection may not occur
(3). What is not known is whether immunosuppression alone, without other factors
peculiar to the transplant recipient, can cause CMV infection. One approach to this
question is to study patients receiving such therapy for reasons other than to prevent
allograft rejection. Patients with rheumatologic disorders were chosen for this pur-
pose because there is no known association between these diseases and CMV.
This investigation may conveniently be divided into two parts. The first was a
prevalence survey conducted among patients attending a rheumatology outpatient
clinic during a 7-month period. Blood and urine samples wereobtained on a single oc-
casion from essentially all clinic attendees. Isolation of CMV was attempted from
buffy coat and urine specimens, and complement-fixing (CF) antibody was measured
on each serum.
Table 1 is a summary of the serologic results among 131 rheumatology clinic
patients. The geometric mean titer and the fraction of rheumatology patients with a
CF titer of > 1:4 are compared to a control group of211 unselected blood donors. As
would be expected in an adult population, both thegeometric mean titer and the frac-
tion who were seropositive increased with age up to 55 years. Above 55, CF titers ap-
peared to level off or even decrease slightly. As shown in Table 1, the geometric
mean titers offemales are greater than those ofmales, both in rheumatology patients
and in blood donors. This relationship between sex and titer is statistically significant
in both ofthese two populations.
Therefore, when the influence of other factors on CMV serology was examined,
appropriate statistical methods to adjust for age and sex differences were used. In
each instance the effect of a particular factor was examined with respect both to the
observed proportion of relevant persons who had antibody and to the magnitude of
the titer among those who were seropositive. In order to adjust for the effects of
varying age and sex distributions when testing for significant differences between
population subgroups in the observed proportion of individuals with antibody,
Mantel-Haenszel summary chi-square statistics (4) were employed. Analysis of
variance techniques were used to identify those variables which are significantly re-
lated to the magnitude of titer among seropositive individuals. By analysis of
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TABLE 1
Cytomegalovirus CF Antibody Titers ofRheumatology Patients and Blood Donors
Rheumatology
patients Blood donors Total
Titer Titer Titer
>1:4 >1:4 >1:4
Sex Number I/GMT (%) Number 1/GMT (%) Number 1/GMT (%)
Male 41 7.5 51.2 109 6.4 50.5 150 6.7 50.7
Female 90 15.8 64.4 102 8.4 55.9 192 11.3 59.9
Total 131 12.5 60.3 211 7.3 53.1 342 9.0 55.8
variance, the effect of any factor was examined after simultaneous adjustment for
every other factor.
As shown in Table 1, both the proportion of rheumatology clinic patients who are
seropositive and their geometric mean titer appear to be higher than blood-donor
controls. However, when adjusted for age and sex, there is no significant difference
between clinic patients and blood donors with respect to either the proportion with
antibody or the magnitude ofthe titer. The only significant source ofvariation within
the combined population is attributable to the effects of sex (P = 0.002), indicating
that the apparent difference between patients and donors is explained by different
distribution ofthe sexes, females predominating in the clinic population.
The antibody titers of clinic patients according to diagnostic categories are shown
in Table 2. It appears that a greater proportion ofpatients with progressive systemic
sclerosis are seropositive, and that those with antibody tend to have a higher titer.
Likewise, it seems that a smaller fraction of systemic lupus erythematosis patients
are seropositive. However, in an analysis adjusted for age and sex, there is no signi-
ficant difference between any diagnostic group and blood-donor controls with respect
to the proportion having titer. Among seropositive rheumatology patients, there is no
significant relationship between diagnosis and magnitude of titer after adjusting for
age.
The effect ofthe therapy employed on the prevalence and magnitude ofCF titers is
presented in Table 3. The proportion ofpatients receiving corticosteroids with titer is
lower than the rest of the clinic population. Despite having a similar proportion who
are seropositive, the titers of seropositive patients receiving cytotoxic immunosup-
pressive drugs appear to be higher than the titers of the remaining patients. These
observations are borne out by appropriate analyses. The proportion of patients on
TABLE 2
Cytomegalovirus CF Antibody Titers in a Rheumatology Clinic Population According to Diagnosis
1/Titer Titer ____________________________________________> 1:8
Diagnosis <4 8 16 32 64 128 >256 Total I/GMT (%)
Progressive systemic
sclerosis 10 1 3 9 9 7 1 40 23.1 75.0
Rheumatoid arthritis 12 0 3 7 1 1 0 24 8.0 50.0
Systemic lupus
erythematosis 7 0 2 0 0 1 1 11 6.6 34.4
Other 23 3 8 9 8 3 2 56 11.0 58.9
Total 52 4 16 25 18 12 4 131 12.5 60.3
78IMMUNOSUPPRESSION AND CMV INFECTION
TABLE 3
Cytomegalovirus CF Antibody in a Rheumatology Clinic Population According toTherapy
1/Titer Titer > 1:8
Therapy <4 8 16 32 64 128 >256 Total 1/GMT (%)
Immunosuppressiona 5 0 0 1 0 5 3 14 30.5 64.3
Corticosteroid 18 1 4 3 4 0 1 31 6.5 41.9
Neither or none 29 3 12 21 14 7 0 86 13.6 66.3
Total 52 4 16 25 18 12 4 131 12.5 60.3
aAzathioprine or cyclophosphamide.
corticosteroids who are seropositive is significantly lower regardless ofwhether com-
parison is made with blood-donor controls or with the remainder ofthe rheumatology
clinic population (P < 0.025). Examination of only those patients who are seroposi-
tive in an analysis of variance adjusted for age, sex, and diagnostic effects reveals a
significant effect oftreatment on titer magnitude (P = 0.02). This is due to the higher
titers of immunosuppressed patients (P = 0.04); the titers of seropositive corti-
costeroid-treated patients are not significantly different from those of clinic patients
on neither form oftherapy.
The results of isolation attempts from buffy coat and urine specimens of the
rheumatology clinic patients are shown in Table4. CMV was not isolated from any of
the 126 available buffy coat specimens. No isolations were made from the urines of
123 patients not receiving azathioprine or cyclophosphamide therapy, including 37
who were on corticosteroids. Three of 15 (20%) patients receiving cytotoxic immuno-
suppressive agents had cytomegalovirus recovered from their urine. This difference
in the prevalence ofviruria between patients receiving and not receiving immunosup-
pressants is highly significant (Fisher's exact test, P = 0.001). All three patients with
viruria had high CF antibody titers. In one of the three viruric patients, it was possi-
ble to correlate the presence ofCMV in the urine with initiation and cessation ofim-
munosuppressive medication. Cyclophosphamide was discontinued in this patient
after the first positive urine was obtained, and a second specimen 3 months later was
negative for virus. At that time, the drug was reinstituted, and cytomegalovirus was
isolated from the urine 7 months later. Therapy was once again stopped and urine,
nearly 10 months thereafter, was again free ofvirus.
To determine when immunosuppressed patients become infected and whether in-
fection is of a primary or reactivation type, a prospective study was undertaken of
patients with a rheumatologic condition who were scheduled to begin a course of
cyclophosphamide, azathioprine or, in one case, chlorambucil. Specimens for isola-
TABLE 4
Frequency ofCytomegalovirus Isolation from the Buffy Coat and Urine ofRheumatology Clinic Patients
Buffy coat Urine Total
Therapy Positive Tested Positive Tested patients
Immunosuppression a 0 14 3 15 15
Corticosteroid 0 31 0 37 37
Other or none 0 81 0 86 89








Prior status Number increase Viruria infected
Seropositive 9 3 5 5 (55.6%)
Seronegative 5 1 0 1(20.0%)
Total 14 4 5 6 (42.9%)
tion attempts and CF antibody determinations were obtained before, and at intervals
following, the initiation of immuossuppressive therapy. Table 5 summarizes the
results to date in the 14 patients studied. CMV was not isolated from buffy coat
specimens in any case. Six of the 14 patients (42.9%) had evidence ofCMV infection
which in each case was first observed between 6 and 12 weeks following the initiation
of the immunosuppressive drug. In five patients, infection wasdemonstrated by isola-
tion of CMV from the urine, preceded or accompanied in three by a fourfold or
greater rise in antibody titer. All five patients who yielded virus in their urine had a
titer of 1:8 or greater prior to initiation of immunosuppressive medication. One
patient who was seronegative prior to therapy manifested CMV infection by sero-
conversion which was not accompanied by viruria. Thus, infection developed in oneof
five (20.0%) seronegative and five ofnine (55.6%) seropositive patients. This relation-
ship, although suggestive, is not statistically significant, perhaps because ofthe small
sample sizes.
These studies reaffirm the increasing prevalence of CMV CF antibody with age
among adults and confirm a previous observation (6) that seropositive females have
significantly higher titers than seropositive males. It is reassuring that rheumatology
clinic patients are not significantly different from controls in respect both to the pro-
portion who are seropositive and to the magnitude of titer, after adjustment for all
other relevant factors. Furthermore, there is no suggestion that serologic or virologic
evidence ofCMV is related to the specific rheumatologic diagnosis. Since the under-
lying disease does not in itself promote CMV infection, patients with rheumatologic
conditions are an appropriate group in which to study the effects oftherapy on infec-
tion.
The proportion of patients treated with corticosteroids who are seropositive is
significantly lower than that of other patients or controls, but the distribution of the
titers ofseropositive patients on corticosteroids is not significantly different. There is
no evidence from this investigation, previous human studies, or results with animals
that corticosteroids in any way protect against infection. The explanation of the
observed lower proportion of corticosteroid-treated patients who are seropositive
may rest with the effect of these agents on antibody production. Recently,
methylprednisolone administration was found to reduce the levels of circulating im-
munoglobulins in normal men (1). It is possible that the maintenance ofCMV anti-
body after primary infection requires constant B lymphocyte stimulation by antigen
during the clinically latent infection, a process interfered with by corticosteroid
administration.
In contrast to corticosteroid therapy, cytotoxic immunosuppressive drugs increase
the magnitude oftiters in seropositive patients but do not significantly affect the pro-
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portion with antibody. In the prospective investigation five of the six patients who
showed evidence ofCMV infection after initiation ofimmunosuppressive therapy had
preexisting antibody titer, indicating that such therapy acts to reactivate clinically
latent, endogenous infection. The serologic and isolation results in the prevalence
survey then result from sampling a partially seronegative, and presumably partially
uninfected, population at varying intervals following initiation of the immunosup-
pressive drug.
The mechanism by which cytotoxic agents promote reactivation of CMV is not
elucidated by the present investigation. These drugs are employed in the allograft
recipient and in rheumatology patients to suppress immunologic responsiveness, and
reduction in immune defense may allow virus activation. Alternatively, potentiation
of CMV could be a result ofdirect effects of cytotoxic agents on the cells harboring
the virus. This possibility is enhanced by the recent report (5) that pretreatment with
the DNA inhibitor, 5-iodo-2'-deoxyuridine, permits normally nonpermissive cells to
support the growth of CMV. We are studying these two alternative mechanisms in
mice.
Assuming that immunosuppressive therapy is the sole determinant for the
development of CMV infection in the rheumatology patient group, their infection
rate can be applied to renal transplant recipients to determine the risk in the latter
ascribable to cytotoxic drugs. As described elsewhere in this volume (2), 21 or our 32
renal allograft recipients developed CMV infection. If the rate ofinfection in immu-
nosuppressed rheumatology patients (42.9%) applies to the transplant recipients,
65% ofinfections in the latter could be explained by the drugs. Moreover, eight often
(80%) seropositive transplant recipients became infected compared with 56% ofsero-
positive rheumatology patients begun on azathioprine, cyclophosphamide, or chlo-
rambucil. By the same reasoning, approximately 70% of cytomegalovirus infections
in seropositive kidney recipients may be due solely to the immunosuppressants em-
ployed. Immunosuppressive therapy appears to be the predominant risk factor in
seropositive renal transplant recipients. The remainder of CMV infections in trans-
plant patients, particularly seronegative recipients, must be explained by other fac-
tors (2).
SUMMARY
The prevalence of complement-fixing antibody to cytomegalovirus (CMV) among
adult rheumatology clinic patients and blood donors was significantly related to age
and sex. After adjustment for age and sex differences, CMV antibody among
patients was influenced by the therapy employed, but not diagnosis. The proportion
of patients receiving corticosteroids who were seropositive was significantly lower
than other patients. Despite having a similar proportion who had antibody, the titers
of seropositive patients receiving cytotoxic immunosuppressive drugs were signi-
ficantly higher. CMV was isolated from the urine of20% ofrheumatology patients on
cytotoxic immunosuppressive drugs but not from those on other forms oftherapy. In
a prospective investigation, 6 of 14 patients begun on cytotoxic immunosuppressants
developed evidence ofCMV infection. Five ofthe six had preexisting CMV antibody,
indicating that immunosuppression acts primarily by reactivating endogenous infec-
tion. It is estimated that about two-thirds of the CMV infections in renal allograft
recipients may be explained by the immunosuppressive therapy employed.82 DOWLING ET AL.
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